Program
Anti-B7-H3/CD28 Bispecific Antibody XmAb808
Also written as “XmAb808” and “XmAb®808”.
Its studies are mostly in Ovarian Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by Xencor.
Furthest: phase 1, since Oct 11, 20222 company-led studies, 1 open or runningNext primary completion: Dec 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xencor | 21 open or running | phase 1since Oct 11, 2022 | Oct 11, 2022 | Dec 2028phase 1 · NCT07593092 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 11, 2022First study: phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT05585034 · 60 enrolled · United States
- May 11, 2026Phase 1 study in Ovarian NeoplasmsNCT07593092 · 90 planned · United States
Ahead
- Dec 2028Primary completion: phase 1 study in Ovarian NeoplasmsNCT07593092
TargetBeta
“A bispecific antibody directed against the tumor-associated antigen (TAA) and immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and the co-stimulatory T-cell surface glycoprotein CD28, ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07593092Ovarian Neoplasms · United States | 1 | Recruiting | Dec 2028 | 90 |
| NCT05585034Squamous Cell Carcinoma of Head and Neck · United States | 1 | Completed | May 20, 2025 | 60 |
How it is read
Names in the registry
- “XmAb808”, 1 entry
- “XmAb®808”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.